Schizophrenia 12 Nov, 2021

Do long-acting injectable antipsychotics have a role in early-phase schizophrenia?

Early intervention and continuous treatment in schizophrenia are key to ensuring good outcomes. This includes determining patient’s treatment goals, developing a relapse prevention plan, and acknowledging adherence issues, but is there a role for long-acting injectable antipsychotics (LAIs)? The case was put forward in this ECNP2020 Satellite symposium.

 

For the latest updates on sea.progress.im, subscribe to our Telegram Channel https://bit.ly/telePiM

Our correspondent’s highlights from the symposium are meant as a fair representation of the scientific content presented. The views and opinions expressed on this page do not necessarily reflect those of Lundbeck.

References

  1. Perkins DO, et al. Am J Psychiatry 2005;162:1785-804.
  2. McGorry PD, et al. World Psychiatry 2008;7:148-56.
  3. Volavka J, Vevera J. Int J Clin Pract 2018;72:e13094.
  4. Phahladira L. et al. Schizophr Res 2019;206:394-9.
  5. Robinson D, et al. Arch Gen Psychiatry 1999;56:241-7.
  6. Emsley R, et al. BMC Psychiatry 2013;13:50.
  7. Kane JM. J Clin Psychiatry 2007;68 Suppl 14:27-30.
  8. Andreasen NC, et al. Am J Psychiatry 2013;170:609-15.
  9. Taipale H, et al. World Psychiatry 2020;19:61-8.
  10. Tiihonen J, et al. Am J Psychiatry 2011;168:603-9.
  11. Weiden PJ, et al. J Clin Psychiatry 2015;76:684-90.
  12. Kane JM, et al. J Clin Psychiatry 2019;80:18m12546.
  13. Kane JM, et al. JAMA Psychiatry 2020;e202076.
  14. Hastrup LH, et al. Br J Psychiatry 2013;202:35-41.
  15. Nordentoft M, et al. Early Interv Psychiatry 2015;9:156-162.